Alouette test (reading test)
OtherThe alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
NCT Number: NCT03958175
Reading disorders in Parkinson's Disease (PD) are poorly evaluated due to the lack of validated tests to screen for them. They are often attributed to hand tremors associated with the disease. In this study, the investigating team evaluated the "alouette test" validated for dyslexia screening, in PD by comparing the results to healthy patients.
Looking for future studies?
Notify MeAll sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
Time frame: 1 day
The Alouette test is based on the precision and speed in reading a short text (279 words). The score corresponds to the total number of words correctly read.
Hospices Civils de Lyon
Other
Screening for Reading Difficulties in Parkinson's Disease: An Evaluation of the Alouette Test
Acronym: REPEAT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04620551
Basal Ganglia Diseases, Brain Diseases
Omaha, Nebraska, United States
View Trial DetailsNCT03192046
Basal Ganglia Diseases, Brain Diseases
Dallas, Texas, United States
View Trial DetailsNCT01496599
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03027310
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial Details